Literature DB >> 29690706

[The analysis of clinical characteristics and disease activity in ankylosing spondylitis patients with hyperuircemia].

X J Zhang1, X M Cui, R Y Chen, H T Sun, J J Zhou, L D Jiang.   

Abstract

Objective: to investigate the clinical characteristics and disease activity in ankylosing spondylitis (AS) patients with hyperuricemia. Method: Laboratory tests, magnetic resonance imaging, disease activity and functional index of AS patients from Fudan University Zhongshan Hospital were collected. T test, square test were applied to investigate the difference between AS patients with hyperuricemia and AS patients with normal serum uric acid in clinical characteristics and disease activity in AS patients. Result: Among all the AS patients, 23.4% (22/94) patients accompanied with hyperuricemia. AS patients accompanied with hyperuricemia showed significant younger age (28.9±7.9 vs 35.8±11.1, P=0.002); higher serum alanine aminotransferase (33.6±23.6 vs 19.8±12.4, P=0.014), aspartate aminotransferase (23.8±8.7 vs 18.6±9.6, P=0.025) and creatinine (78.4±12.5 vs 69.8±13.3, P=0.009), lower Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (11.2±8.8 vs 17.9±12.0, P=0.027) and Bath Ankylosing Spondylitis Functional Index (BASFI) (0.7±0.9 vs 1.8±2.2, P=0.002) compared with AS patients whose serum uric acid level is normal.
Conclusion: AS Patients with younger age, impaired hepatic and renal funtion and lower scores in BASDAI and BASFI tend to accompany with hyperuricemia.

Entities:  

Keywords:  Hyperuricemia; Magnetic resonance imaging; Sacroiliac joint; Spondylitis

Mesh:

Substances:

Year:  2018        PMID: 29690706     DOI: 10.3760/cma.j.issn.0376-2491.2018.13.006

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  1 in total

1.  The serum uric acid is longitudinally related to patients global assessment of disease activity in male patients with axial spondyloarthritis.

Authors:  Meimei Cai; Wen Liu; Yuanhui Wu; Qing Zheng; Dehao Liu; Guixiu Shi
Journal:  BMC Musculoskelet Disord       Date:  2022-07-27       Impact factor: 2.562

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.